Why We Are Optimistic About The Long-Term Outlook For Health Care

The healthcare sector experienced significant underperformance in Q2 2025, primarily due to unprecedented policy uncertainty and proposed spending cuts, notably the Trump administration's 'One Big Beautiful Bill Act' (OBBBA) which enacts over $1 trillion in Medicaid cuts, alongside concerns regarding NIH funding, FDA operations, and drug pricing. These measures, including new Medicaid work requirements and potential ACA subsidy expirations, are projected to increase the uninsured population and pressure hospital finances and managed care enrollment. Despite these near-term headwinds, the fund maintains a long-term bullish outlook, citing robust secular growth drivers such as an aging population and significant innovation, asserting that policy changes are largely priced in and historical data supports the sector's long-term outperformance.

Analysis

The healthcare sector experienced significant underperformance in the second quarter of 2025, lagging its benchmark by over 17% due to substantial policy-driven uncertainty. The newly enacted 'One Big Beautiful Bill Act' (OBBBA) introduces over $1 trillion in healthcare spending cuts over a decade, primarily from Medicaid, and institutes work requirements projected to increase the uninsured population by millions. This, combined with the potential year-end expiration of ACA subsidies, poses direct revenue and cost pressures on hospitals and managed care companies. Further headwinds stem from proposed 40% cuts to the NIH budget, which impacts life sciences tools companies, and the threat of new drug pricing policies like Most-Favored-Nation (MFN), creating earnings uncertainty for pharmaceutical and biotechnology firms. Despite these near-term challenges, a long-term positive outlook is maintained, anchored by powerful secular growth drivers, including the aging U.S. population and robust innovation exemplified by companies like Eli Lilly (LLY) and Boston Scientific (BSX). The thesis posits that these policy headwinds are largely priced into current valuations and may be moderated by legal challenges and political pushback, while historical data suggests the sector tends to outperform the broader market over longer, 5- and 10-year rolling periods.

Key Decisions for Investors

• Investors should prioritize exposure to companies with strong innovative pipelines and clear competitive advantages, such as those in GLP-1s, advanced medical devices, and AI-driven diagnostics, which are better positioned to transcend macroeconomic and policy pressures.
• Closely monitor key political and legal catalysts, including the final congressional NIH budget, legal challenges to the OBBBA and MFN drug pricing, and any potential extension of ACA subsidies, as these events represent significant inflection points for sector sentiment and company earnings.
• The current sector weakness may present a strategic entry point for investors with a long-term horizon, but caution is warranted for the short-term due to the high degree of policy uncertainty impacting sub-sectors like managed care and hospitals most directly.
• Differentiate between sub-sectors, as companies focused on an innovation-driven product cycle may offer more resilience than those directly exposed to government reimbursement models, such as hospitals and Medicaid-focused managed care organizations.